2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Gil-Manso, R, Calleja, CH, Tornero, LP, Cabero-Martínez, A, García-Bacelar, A, López, AAM, Cabrero, M, Baile, M, Pérez-López, E, Pita, AA, López, LV, Rodriguez, Jí, Gutiérrez, MDG, Sánchez-Guijo, F, López-Corral, L. Nabiximols oromucosal spray in patients with chronic graft-versus-host disease: effects on sclerodermatous features and refractory muscle cramps. BONE MARROW TRANSPL -. 1 jul 2025. 1 jul 2025. . F.I.:4,500 [doi:10.1038/s41409-025-02665-4]
Velarde, AT, Lopez-Perez, J, Calzada, N, Balas, A, Gil-Etayo, FJ. HLA-DRB5*01:133, the First HLA-DRB5 Allele With Arginine at Position 16 in the Peptide-Binding Domain. HLA 106 -. 1 jul 2025. . . F.I.:5,900 [doi:10.1111/tan.70321]
Peña-Lorenzo, D, Rebollo, N, Sanchez-Hernández, JG, Vázquez-López, L, Otero, MJ, Zarzuelo-Castañeda, A. Optimization of Isavuconazole Dosing in Patients with Invasive Fungal Infections Through Therapeutic Drug Monitoring: Real-World Clinical Practice Experience. LIFE-BASEL 15 -. 12 jun 2025. . . F.I.:3,200 [doi:10.3390/life15060946]
López-Pérez, J, Gil-Etayo, FJ, Parra, AV, Hernaz, IJ, Velarde, AT. A Missense Substitution in Exon 2 Generates the First HLA-DQB1*04 Allele With Glutamine at Residue 52, DQB1*04:108. HLA 105 -. 1 may 2025. . . F.I.:5,900 [doi:10.1111/tan.70265]
Alejo, E, Agulló, C, Puertas, B, Eiros, R, Rey-Búa, B, Barnés, C, Rodríguez-González, M, López-Corral, L, Santos-Briz, A, Escalante, F, Pérez-García, ML, Jiménez-Cabrera, S, Gutiérrez, NC, Puig, N, Mateos, MV, González-Calle, V. Impact of the Addition of Daratumumab to the Frontline Treatment of Patients with Immunoglobulin Light-Chain Amyloidosis: A Single-Centre Experience. CANCERS 17 -. 25 abr 2025. . . F.I.:4,500 [doi:10.3390/cancers17091440]

Díez, P, Juanes-Velasco, P, García-Vaquero, ML, Droste, C, Landeira-Viñuela, A, Alcoceba, M, Fidalgo-Gómez, H, Misiego-Herrero, S, Navarro-Bailón, A, Baile, M, Bastida, JM, Sanchez-Santos, JM, Góngora, R, Almeida, J, Gonzalez-Diaz, M, Orfao, A, De Las Rivas, J, Fuentes, M. Tonic signaling of the B-cell antigen-specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages. MOL ONCOL -. 25 mar 2025. 1 mar 2025. . F.I.:5,000 [doi:10.1002/1878-0261.70032]

Sánchez-González, JL, Fernández-Rodríguez, EJ, Méndez-Sánchez, R, Polo-Ferrero, L, Puente-González, AS, De Ramón, C, Marcos-Asensio, S, Blázquez-Benito, P, Navarro-Bailón, A, Sánchez-Guijo, F, Martín-Sánchez, C. Effects of a strength physical exercise program in chronic lymphocytic leukemia patients on quality of life, mental health, and frailty: a randomized controlled trial study protocol. FRONT SPORTS ACT LIV 7 -. 10 mar 2025. . . F.I.: [doi:10.3389/fspor.2025.1534861]

Zugas, Ines, Tormo-Ratera, Marta, Oliver-Caldes, Aina, Soler-Perromat, Juan Carlos, Gonzalez-Calle, Veronica, Moreno, David F., Cabanas, Valentin, Lopez-Munoz, Nieves, Bartolome-Solanas, Alvaro, Espanol-Rego, Marta, Reguera-Ortega, Juan Luis, Rosinol, Laura, Lopez-Corral, Lucia, Tovar, Natalia, Rodriguez-Lobato, Luis Gerardo, Perez, Rosa Maria Alvarez, Varea, Sara, Olesti, Eulalia, Gomez-Grande, Adolfo, Frutos, Laura, Tamayo, Pilar, Juan, Manel, Moraleda, Jose M., Urbano-Ispizua, Alvaro, Gonzalez-Navarro, E. Azucena, Martinez-Lopez, Joaquin, Mateos, Maria-Victoria, Tomas, Xavier, Setoain, Xavier, de Larrea, Carlos Fernandez. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma. BLOOD ADV 9 571-582. 11 feb 2025. . . F.I.:7,400 [doi:10.1182/bloodadvances.2024014360]
Raj, K, Eikema, DJ, Lawless, S, Koster, L, Kunadt, D, Kröger, N, Platzbecker, U, Stelljes, M, Bethge, W, Holderried, T, Fanin, R, Zeiser, R, Kuball, J, Leblond, V, Nicholson, E, Passweg, J, Potter, V, Bay, JO, Bazarbachi, A, Corral, LL, Gurnari, C, Scheid, C, Drozd-Sokolowska, J, Morris, TC, Hayden, P, Yakoub-Agha, I, Robin, M, Mclornan, DP. Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. BONE MARROW TRANSPL 60 220-226. 1 feb 2025. 1 nov 2024. . F.I.:4,500 [doi:10.1038/s41409-024-02462-5]
Zabaleta, A, Puig, N, Cedena, MT, Oliver-Caldes, A, Perez, JJ, Moreno, C, Tamariz-Amador, LE, Rodriguez-Otero, P, Prosper, F, Gonzalez-Calle, V, López-Corral, L, Rey-Búa, B, Puertas, B, Mirás, F, Sánchez-Pina, J, López-Muñoz, N, Juan, ME, González-Navarro, E, Urbano, A, de Larrea, C, Blade, J, Lahuerta, JJ, Martinez-Lopez, J, Mateos, MV, San Miguel, JF, Paiva, B. Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy. AM J HEMATOL 100 93-102. 1 ene 2025. 1 nov 2024. . F.I.:10,100 [doi:10.1002/ajh.27526]